226 related articles for article (PubMed ID: 25463533)
1. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
[TBL] [Abstract][Full Text] [Related]
2. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
[TBL] [Abstract][Full Text] [Related]
3. Bsep/Abcb11 knockout ameliorates Schistosoma mansoni liver pathology by reducing parasite fecundity.
Macháček T; Fuchs CD; Winkelmann F; Frank M; Scharnagl H; Stojakovic T; Sombetzki M; Trauner M
Liver Int; 2023 Nov; 43(11):2469-2478. PubMed ID: 37641872
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
5. Preventive CTLA-4-Ig Treatment Reduces Hepatic Egg Load and Hepatic Fibrosis in
Sombetzki M; Rabes A; Bischofsberger M; Winkelmann F; Koslowski N; Schulz C; Reisinger EC
Biomed Res Int; 2019; 2019():1704238. PubMed ID: 31950032
[TBL] [Abstract][Full Text] [Related]
6. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
[TBL] [Abstract][Full Text] [Related]
7. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
8. Anti-L3T4 antibody treatment suppresses hepatic granuloma formation and abrogates antigen-induced interleukin-2 production in Schistosoma mansoni infection.
Mathew RC; Boros DL
Infect Immun; 1986 Dec; 54(3):820-6. PubMed ID: 3096893
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immune responses of Schistosoma mansoni-infected mice with distinct chronic forms of the disease.
Silva LM; Oliveira SA; Ribeiro-dos-Santos R; Andrade ZA; Soares MB
Acta Trop; 2004 Jul; 91(2):189-96. PubMed ID: 15234668
[TBL] [Abstract][Full Text] [Related]
11. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Moustafa T; Fickert P; Magnes C; Guelly C; Thueringer A; Frank S; Kratky D; Sattler W; Reicher H; Sinner F; Gumhold J; Silbert D; Fauler G; Höfler G; Lass A; Zechner R; Trauner M
Gastroenterology; 2012 Jan; 142(1):140-151.e12. PubMed ID: 22001865
[TBL] [Abstract][Full Text] [Related]
12. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E; Eller K; Pollheimer MJ; Racedo S; Kirsch AH; Frauscher B; Wahlström A; Ståhlman M; Trauner M; Grahammer F; Huber TB; Wagner K; Rosenkranz AR; Marschall HU; Fickert P
J Hepatol; 2017 Jul; 67(1):110-119. PubMed ID: 28242240
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological approach to reverse portal hypertention and hepatic schistosomal fibrosis in Egypt, control experimental study.
Helmy AH; Abdel-Hady AA; el-Shanawany F; Hammam O; Abdel-Hady A
J Egypt Soc Parasitol; 2005 Dec; 35(3):731-50. PubMed ID: 16333884
[TBL] [Abstract][Full Text] [Related]
14. Single-sex infection with female Schistosoma mansoni cercariae mitigates hepatic fibrosis after secondary infection.
Koslowski N; Sombetzki M; Loebermann M; Engelmann R; Grabow N; Österreicher CH; Trauner M; Mueller-Hilke B; Reisinger EC
PLoS Negl Trop Dis; 2017 May; 11(5):e0005595. PubMed ID: 28542175
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis.
Chatterjee S; Vrolix G; Depoortere I; Peeters T; Van Marck E
BMC Infect Dis; 2005 Jun; 5():45. PubMed ID: 15949036
[TBL] [Abstract][Full Text] [Related]
16. Role of cytokines in the formation and downregulation of hepatic circumoval granulomas and hepatic fibrosis in Schistosoma mansoni-infected mice.
Cheever AW; Jankovic D; Yap GS; Kullberg MC; Sher A; Wynn TA
Mem Inst Oswaldo Cruz; 1998; 93 Suppl 1():25-32. PubMed ID: 9921320
[TBL] [Abstract][Full Text] [Related]
17. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
19. Role of the IL-33/ST2 Activation Pathway in the Development of the Hepatic Fibrosis Induced by
Maggi L; Camelo GMA; Rocha IC; Pereira Alves W; Moreira JMP; Almeida Pereira T; Tafuri WL; Rabelo ÉML; Correa A; Ecco R; Negrão-Corrêa DA
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373379
[No Abstract] [Full Text] [Related]
20. Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.
Buko VU; Lukivskaya OY; Naruta EE; Belonovskaya EB; Tauschel HD
J Clin Exp Hepatol; 2014 Dec; 4(4):293-301. PubMed ID: 25755576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
